Apollo Technology Capital Corporation, a significant shareholder of MediPharm Labs Corp., has issued voting recommendations ahead of the company's 2025 Annual and Special Meeting of Shareholders scheduled for June 16. Apollo Capital, owning approximately 3.0% of MediPharm's common stock, urges shareholders to disregard MediPharm's green proxy card and instead vote for the gold proxy card in support of Apollo Capital's six director nominees. These nominees-John Fowler, Alan D. Lewis, David Lontini, Demetrios Mallios, Regan McGee, and Scott Walters-are presented as highly qualified candidates capable of addressing issues such as strategic failures and excessive executive compensation at MediPharm. Apollo Capital has launched a campaign website, CureMediPharm.com, to outline their five-pillar plan aimed at restoring value and accountability to the company.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。